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Abstract
Background: Current prophylactic vaccines against human papillomavirus (HPV) target two oncogenic types (16 and 18)
that contribute to 70% of cervical cancer cases worldwide. Our objective was to quantify the range of additional benefits
conferred by second-generation HPV prophylactic vaccines that are expected to expand protection to five additional
oncogenic types (31, 33, 45, 52 and 58).
Methods: A microsimulation model of HPV and cervical cancer calibrated to epidemiological data from two countries
(Kenya and Uganda) was used to estimate reductions in lifetime risk of cervical cancer from the second-generation HPV
vaccines. We explored the independent and joint impact of uncertain factors (i.e., distribution of HPV types, co-infection
with multiple HPV types, and unidentifiable HPV types in cancer) and vaccine properties (i.e., cross-protection against non-
targeted HPV types), compared against currently-available vaccines.
Results: Assuming complete uptake of the second-generation vaccine, reductions in lifetime cancer risk were 86.3% in
Kenya and 91.8% in Uganda, representing an absolute increase in cervical cancer reduction of 26.1% in Kenya and 17.9% in
Uganda, compared with complete uptake of current vaccines. The range of added benefits was 19.6% to 29.1% in Kenya
and 14.0% to 19.5% in Uganda, depending on assumptions of cancers attributable to multiple HPV infections and
unidentifiable HPV types. These effects were blunted in both countries when assuming vaccine cross-protection with both
the current and second-generation vaccines.
Conclusion: Second-generation HPV vaccines that protect against additional oncogenic HPV types have the potential to
improve cervical cancer prevention. Co-infection with multiple HPV infections and unidentifiable HPV types can influence
vaccine effectiveness, but the magnitude of effect may be moderated by vaccine cross-protective effects. These benefits
must be weighed against the cost of the vaccines in future analyses.
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Introduction
Prophylactic vaccines against human papillomavirus (HPV),
responsible for all cervical cancers and a smaller proportion of
other anogenital and oral cancers, represent one of the major
breakthroughs in cancer prevention. The two currently available
HPV vaccines, which target two of the most oncogenic types,
HPV-16 and -18, have the potential to prevent about 70% of
cervical cancer cases worldwide; the 4-valent vaccine also targets
two non-oncogenic types, HPV-6 and -11, responsible for genital
warts. In settings that have not successfully implemented organized
cervical cancer screening programs, the introduction of HPV
vaccination may provide a critical opportunity for primary
prevention of cervical cancer; in settings with organized screening,
vaccination could also provide the opportunity to reduce the
intensity of screening programs. Indeed, HPV vaccination of
young adolescent girls has been shown to be cost-effective in both
developed and developing countries [1–5].
Despite the great promise for prevention of cervical cancer and
other HPV-related cancers, there are several characteristics of
current HPV vaccines that may limit their success. Although the 4-
valent HPV vaccine has been offered at an unprecedented price
($5 per dose) to the GAVI Alliance, the vaccines remain
unaffordable in many parts of the world. Furthermore, the
requirement of cold chain in storage and distribution adds another
logistical challenge in vaccine accessibility and feasibility. Given
regional variation in the proportion of cervical cancers attributable
to HPV-16 and -18, the maximum impact of vaccination may be
lower than 70%. For example, in Kenya where about 60% of
cervical cancers are attributable to HPV-16,-18, reduction in
cancer cases could be 10–20% lower than in Uganda, where up to
75% of cervical cancers are attributable to HPV-16,-18.
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clinical trials, may hold several advantages over the current
vaccines, including protection against additional oncogenic HPV
types, less dependence on cold chain storage and distribution, and
more efficient delivery mechanisms (e.g., oral and mucosal routes
instead of the parenteral route), facilitating integration with other
childhood vaccines in routine immunization programs [6,7]. The
second-generation prophylactic HPV vaccine that is most
advanced in the pipeline (clinical trial phase III) is a 9-valent
(‘‘nonavalent’’) vaccine [8]. In addition to the types in the current
4-valent (‘‘quadrivalent’’) vaccine (i.e., 6, 11, 16, and 18), the 9-
valent vaccine targets five new oncogenic HPV types (i.e., 31, 33,
45, 52, and 58) and has the potential to offer an additional 15–
30% reduction in cervical cancer incidence. However, the actual
population-level impact will depend on several complicating
factors, including: a) the proportion of cancer cases attributable
to HPV types targeted by the vaccine, b) the proportion of cancer
cases attributable to unidentifiable HPV types, c) the prevalence of
co-infections with multiple HPV types, and d) vaccine cross-
protective effects against other oncogenic types not covered by the
vaccine.
The objective of this study is to provide preliminary estimates of
the potential health benefits from the anticipated 9-valent HPV
vaccine, exploring the independent and combined effects of these
factors. Since reductions in cervical cancer cases are not expected
to be observed for several years post-vaccination, disease
simulation models that are carefully developed to incorporate
information on HPV epidemiology and cervical carcinogenesis
can be used to project a range of estimated benefits in the absence
of long-term empiric data and under conditions of uncertainty.
Used in a decision-analytic framework, such disease simulation
models can inform policy makers on how to design new or
restructure existing cervical cancer prevention programs in the
rapid wake of new technologies [9–14].
Methods
We used an established cervical cancer disease simulation model
that had been previously calibrated to two separate countries,
Kenya and Uganda, to estimate health benefits in terms of
reductions in lifetime risk of cervical cancer from the 9-valent
prophylactic HPV vaccine. We selected these two representative
countries because of their high cervical cancer incidence rates, the
lack of organized cervical cancer screening or HPV vaccination
programs, and the different proportions of cervical cancer cases
attributable to HPV types 16 and 18. These models had previously
been calibrated to fit to epidemiological and clinical data from the
respective countries and used to explore the cost-effectiveness of
HPV vaccination and cervical cancer screening in five Eastern
African countries [1].
We conducted a series of exploratory analyses to estimate both
the absolute and incremental benefits of the 9-valent HPV
prophylactic vaccine, compared with the benefits from currently-
available HPV vaccines (i.e., 2-valent and 4-valent). The influence
of several important factors was explored, separately and
concurrently:
I. HPV Type Distribution
The higher the prevalence the vaccine-targeted HPV types are
in cervical cancer, the greater the expected reductions in cases
from the 9-valent vaccine. Globally, HPV types 16, 18, 31, 33, 45,
52 and 58 are detected in approximately 91.6% (95% CI: 88.5–
95.1%) of squamous cell cervical cancers [15,16]. These seven
oncogenic types are associated with 89.4% and 91.4% of cervical
cancer cases in Uganda and Kenya, respectively [17–20].
While the total benefit in cervical cancer prevention from the 9-
valent vaccine may not vary much across settings, the incremental
benefit compared with the benefit of the current vaccines that
target only HPV-16 and -18 could vary greatly across populations,
depending on the prevalence of these types and the newly-targeted
HPV types (i.e., 31, 33, 45, 52 and 58) in cervical cancer. For
example, in Kenya, where HPV-16 and -18 contribute to roughly
62.2% of cervical cancer cases, HPV types 31, 33, 45, 52 and 58
are detected in 30.1% of all cases. In contrast, in Uganda, HPV-16
and -18 contribute to 73.9% – and the five other oncogenic types
to 17.4% – of cervical cancer cases. Consequently, the added
benefits of the 9-valent vaccine over the current vaccines in Kenya
could be nearly double the added benefits in Uganda.
To estimate the potential benefit of the 9-valent vaccine in
reducing cervical cancer risk, we obtained and used the prevalence
of each of the seven oncogenic HPV types targeted by the 9-valent
vaccine as the basis to estimate their joint contributions to cancer
cases. In Kenya, 62.2% of cervical cancers are caused by HPV-16
and/or -18; [20] the remaining 37.8% of cancer cases are caused
by non-16/18 oncogenic HPV types and therefore could possibly
be averted by the 9-valent vaccine. We estimated the potential
cancer reduction in these 37.8% of cases by calculating the
weighted proportions of HPV types 31, 33, 45, 52 and 58 relative
to all the non-16/18 oncogenic HPV types. Based on country-
specific data on the genotype distribution in cervical cancer cases
in Kenya, [18,20] this proportion is 69.0% and can be interpreted
as the contribution of the five newly-targeted oncogenic HPV
types in causing cancer among those cases that are not caused by
HPV-16 and/or -18. Therefore, solely on the basis of the
distribution of HPV types, an additional 69.0% of 37.8% (i.e.,
26.1%) of all cervical cancer cases could be reduced from the 9-
valent vaccine in Kenya (Figure 1A).
For Uganda, 73.9% of cervical cancer cases are attributable to
HPV-16 and/or -18; [19] therefore, the remaining 26.1% of cases
are caused by non-16/18 HPV types that may be included in the
9-valent vaccine. Using the proportion of the five newly-targeted
HPV types relative to all non-16/18 types in Uganda, [17,19] an
additional 71.9% of those 26.1% (i.e., 18.8%) of cervical cancer
cases could be reduced from the 9-valent vaccine in Uganda
(Figure 1B).
II. Co-infection with Multiple HPV Types
When there is more than one HPV type present as the possible
cause of cervical cancer, the estimation of vaccine efficacy solely
on HPV type distribution could be inaccurate. It is plausible that
when more than one HPV type is detected, only one of them is the
actual cause of cervical cancer while the other HPV type(s) is(are)
just an incidental finding. However, it is also plausible in some
cases that there is a required synergistic effect between more than
one HPV type in causing cervical cancer. With these diverse
biological possibilities, the added benefit of a 9-valent vaccine
could be overestimated or underestimated in the cases where
multiple HPV types are identified (see Appendix S1 for example
scenarios). Based on the empirical data, 5.4% of cervical cancer
cases in Kenya and 1.1% of cases in Uganda are associated with
more than one of the non-16/18 HPV types [17,18].
III. Unidentifiable HPV Types
The proportion of cervical cancer cases that are attributable to
HPV infection of unknown genotype could also impact estimates
of vaccine benefit. For example, on one extreme, all cases with
unidentifiable HPV infections may be caused by one of the
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vaccine, implying that the 9-valent vaccine would yield greater
benefits than current vaccines. In contrast, all cases with
unidentifiable HPV infections could be caused by HPV types that
are not targeted by the 9-valent vaccine or are already targeted by
the current vaccines, yielding no additional benefits. Based on
empirical data, 3.4% of cervical cancer cases in Kenya and 4.4%
of cases in Uganda are associated with HPV of unknown type
[17,18].
Based on these three sources of uncertainty, we constructed and
analyzed three extreme scenarios in our study, assuming among
cervical cancer cases that: (A) there is no overlap between
unidentifiable HPV types and multiple infections with HPV types
that are targeted by the 9-valent vaccine, and therefore, the 9-
valent vaccine does not offer any benefit in these cases (Figure 2A
for Kenya and Figure 3A for Uganda), (B) there is some overlap
between unidentifiable HPV types and multiple infections with
vaccine-targeted HPV types, and therefore, the 9-valent vaccine
has the ability to prevent some cases with unidentifiable types and
multiple infections, defined as a function of the prevalence of the
five targeted HPV types relative to the prevalence of all non-16/18
types (Figure 2B for Kenya and Figure 3B for Uganda), and (C)
there is complete overlap between unidentifiable HPV types and
multiple infections with vaccine-targeted HPV types and therefore
the 9-valent vaccine offers full protective benefits in cases with an
unidentifiable type and multiple infections (Figure 2C for Kenya
and Figure 3C for Uganda).
IV. Vaccine Cross-protection
Clinical trials have demonstrated that current HPV vaccines
exhibit cross-protective effects against non-16/18 oncogenic types,
[21–23] including the five oncogenic types that are included in the
9-valent vaccine, in which case the added benefit of the 9-valent
vaccine over the current vaccines may be diminished. When
unadjusted for co-infection with multiple HPV types, this cross-
protective effect associated with the bivalent vaccine was estimated
in clinical trials to be roughly 53.0% in preventing precancerous
lesions caused by HPV types 31, 33, 45, 52, or 58, and 61.9% for
lesions caused by any oncogenic HPV type [21–23]. After
adjustment for co-infections between (a) HPV-16 or -18 and (b)
other non-16,-18 oncogenic types, the estimate of cross-protection
against lesions decreased to 37.4% [21]. It is also possible that the
9-valent vaccine itself will exhibit cross-protective effects against
other non vaccine-targeted HPV oncogenic types in a similar
manner as the current vaccines.
We incorporated cross-protective effects against other non-
vaccine types into our existing Scenarios A, B and C with four
possible levels of cross-protection: (1) none (0% cross-protection),
(2) low (7.4% cross-protection), (3) moderate (37.4% cross-
protection), and (4) high (58.2% cross-protection) [21]. By varying
all sources of uncertainty simultaneously, the simulation model can
determine a full range of potential benefits from the 9-valent
vaccine. Overall population absolute benefit would be expected to be
lowest in a scenario where none of the cases with multiple HPV
infections and unidentifiable HPV type were caused by HPV
infections targeted by the 9-valent vaccine. The most favorable
scenario for the 9-valent vaccine would be if all cancer cases with
multiple HPV infections and unidentifiable HPV types were
attributable to at least one of the newly-targeted HPV types and
were fully protected by the 9-valent vaccine.
Model Inputs and Assumptions
Several assumptions were required for the analysis: (a) girls
receive the vaccine (either the 9-valent HPV vaccine or the current
HPV-16,-18 vaccines) by age 12 prior to sexual debut; and (b) all
vaccine recipients complete the full three-dose series (100%
vaccine compliance rate) that is required for current vaccines
and was assumed for the 9-valent vaccine. The primary outcomes
were absolute and relative reductions in lifetime risk of cervical
cancer, compared to no intervention.
Results
Figure 4 shows the absolute reductions in lifetime risk of cervical
cancer by the currently available HPV-16/18 vaccines and by the
9-valent HPV vaccine under scenarios A, B, and C across the four
different assumptions of vaccine cross-protection against non-
vaccine HPV types.
For the current vaccines, the absolute reductions in lifetime risk
of cervical cancer were 60.2% in Kenya and 73.9% in Uganda.
Assuming vaccine cross-protection against non-vaccine types,
these reductions increased to 81.9% in Kenya and 88.2% in
Uganda.
In Scenario A, the 9-valent vaccine yielded absolute risk
reductions of approximately 79.8% in Kenya and 87.9% in
Uganda, when there was no cross-protection against non-vaccine
types. The reductions were as high as 91.0% in Kenya and 94.5%
Figure 1. Potential benefits of the 9-valent vaccine by HPV type
distribution. The whole pie chart represents all cervical cancer cases in
Kenya (1A) and in Uganda (1B). The slice of the blue pie on the right
depicts that cases that caused by non-16/18 types. The bar graph
adjacent to the blue pie slice shows the proportion of the non-16/18
cases that are the 9-valent vaccine target and are not the 9-valent
vaccine target.
doi:10.1371/journal.pone.0048426.g001
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PLOS ONE | www.plosone.org 3 November 2012 | Volume 7 | Issue 11 | e48426Figure 2. Potential benefits of the 9-valent vaccine by HPV type distribution, multiple HPV infections and unidentifiable types in
Kenya. The whole pie chart represents all cervical cancer cases in Kenya. The slice of the blue pie on the right depicts those cases that caused by
non-16/18 types. The bar graph adjacent to the blue pie slice shows the proportion of the non-16/18 cases that are associated with multiple
infections and unidentifiable types. The remaining non-16/18 cases were estimated to be the 9-valent vaccine target and non-target by their HPV
prevalence. In the bar chart adjacent to the pie, blue shading depicts the cases that could be prevented by the 9-valent vaccine. In Scenario A, the 9-
valent vaccine could not offer any benefit to prevent cervical cancer with unidentifiable type and multiple infections. In Scenario B, the 9-valent
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non-vaccine types.
In Scenario B, the 9-valent vaccine increased absolute risk
reductions to approximately 86.3% in Kenya and 91.8% in
Uganda, without cross-protection against non-vaccine types, and
were as high as 93.9% in Kenya and 96.2% in Uganda, with high
levels of cross-protection against non-vaccine types.
In Scenario C, the reductions in lifetime risk of cervical cancer
associated with the 9-valent vaccine were greatest, ranging from
89.3% to 95.2% in Kenya and 93.4% to 96.9% in Uganda,
depending on assumptions of cross-protection.
Discussion
Across varied scenarios of uncertainty, our simulation model
projects that the 9-valent vaccine could reduce lifetime risk of
cervical cancer by 79.8% to 95.2% in Kenya and 87.9% to 96.9%
in Uganda. In comparison, currently-available vaccines could offer
protection against 60.2% to 81.9% of cervical cancers in Kenya
and 73.9% to 88.2% of cervical cancers in Uganda. The added
benefits of the 9-valent vaccine over current vaccines therefore
ranged from 9.2% to 29.1% in Kenya and from 6.3% to 19.5% in
Uganda.
Our study provides evidence that uncertainties surrounding
HPV type distribution in cancer, unidentifiable HPV types, co-
infection with multiple HPV infections, and cross-protection
against non-vaccine types can lead to variable estimates of both
the absolute and incremental benefits of the 9-valent vaccine. The
added benefits were most favorable when the 9-valent vaccine
could fully protect against unidentifiable HPV types and multiple
infections (Scenario C) with an assumption that none of the
vaccines provide cross-protection against non-vaccine HPV types.
The added benefits were least favorable when cases with
unidentifiable types and multiple infections were not attributable
to types targeted by the 9-valent vaccine (Scenario A) with an
assumption that all the vaccines provide high cross-protection
against non-vaccine types.
As expected, HPV type distribution in cancer had a greater
impact on the added benefits of the 9-valent vaccine (compared to
current vaccines) than the absolute benefits. Results showed that
the added benefit of the 9-valent vaccine in Kenya, where cervical
cancer is less attributable to HPV-16 and -18, was approximately
1.5 times greater than in Uganda, where cervical cancer is more
commonly caused by HPV-16 and/or -18. The greater magnitude
in added benefits in Kenya persisted in all scenarios from no cross-
protection to a high level of cross-protection and from no benefit
(Scenario A) to full benefit (Scenario C) against unidentifiable
types and multiple infections.
This finding suggests that in a geographic area where cervical
cancer is less attributable to HPV-16 and -18, the 9-valent vaccine
could offer greater added benefits, compared to the current
vaccines. Based on epidemiological data of HPV type distribution
in cancer from the WHO/ICO Information Centre on Human
Papilloma Virus (HPV) and Cervical Cancer (available at http://
www.who.int/hpvcentre/en/), roughly 68.0%, 68.5%, 70.3%,
73.0% and 75.1% of cervical cancer cases were associated with
HPV-16 and -18 in Asia, Africa, the Americas, Europe and
Oceania continents, respectively [24]. Therefore, based on the
type distribution of HPV -16 and -18 in cervical cancer alone,
populations in Asia could possibly gain relatively higher added
benefits from the 9-valent vaccine than other populations. Based
on the reported prevalence of the five additional HPV types in
cervical cancer targeted by the 9-valent vaccine, up to 26.6%,
20.5%, 18.0%, 14.2% and 3.1% of cervical cancer cases in Asia,
Africa, Americas, Europe and Oceania continents could be
prevented by the 9-valent vaccine [24]. As showcased in our
analysis, in addition to the causal attribution of HPV genotypes,
other important factors such as the prevalence of multiple
infections, prevalence of unidentifiable types, vaccine cross-
protective properties, and the availability of a cervical cancer
screening program in a particular population must be taken into
consideration. Distributive patterns of HPV types in cervical
cancer can vary greatly across countries within the same continent
as was shown in Kenya and Uganda. As a result, specific
epidemiological data in the population of interest should be used
when available to estimate the context-specific benefits of the 9-
valent vaccine.
Our results also suggest that uncertainty from unidentifiable
HPV types and co-infection with multiple HPV types could affect
the lifetime risk reductions in cervical cancer by approximately
4.2–9.5% in Kenya and approximately 2.4–5.5% in Uganda,
based on the difference between the two extreme scenarios
(Scenarios A and C) with the varying degrees of cross-protection
against non-vaccine types. The impact of the uncertainty from
unidentifiable types and co-infection with multiple types decreased
as the level of cross-protection against non-vaccine types increased.
Cross-protection against non-vaccine types was expected to
reduce the added benefits of the 9-valent vaccine over the benefits
from the current vaccines. Our results demonstrated that, with
moderate cross-protection against non-vaccine types, the added
benefits from the 9-valent vaccine could decrease by 6.4–9.8% in
Kenya and by 4.8–6.7% in Uganda, compared to no cross-
protection against non-vaccine types. With high cross-protection
against non-vaccine types, the added benefits from the 9-valent
vaccine were reduced by 10.5–15.8% in Kenya and by 7.7–10.8%
in Uganda, in comparison to a scenario with no cross-protection.
The findings from our exploratory analysis underscore that
estimates of the incremental benefits from the 9-valent HPV
vaccine compared to the current HPV-16/18 vaccines may vary
widely subject to several uncertainties, ranging from cancer
reductions of 9.2% to 29.1% in Kenya and 6.3% to 19.5% in
Uganda. Despite the utility of our disease simulation model in
projecting preliminary estimates of population-level vaccine
benefits under complex interactions of various uncertainties, our
analysis has several limitations. First of all, we did not model the
infection from each of the HPV types individually. We classified all
non-16, non-18 HPV types into either the group of five additional
types targeted by the 9-valent vaccine or the group of the
remainder types. We then made a simplifying assumption that the
contributions to cervical cancers from all of these non-16, non-18
types were directly proportionate to their prevalence in non-16,
non-18 cancer cases. This estimation may be imprecise if some
oncogenic HPV types are more likely than others to be incidental
infections, but in the absence of such information, we only
modeled the contributions to cervical cancer based on prevalence.
Secondly, we did not vary the levels of vaccine uptake and
adherence to the full three-dose vaccine series. Perfect vaccine
uptake is unlikely even in developed countries. Indeed, a recent
vaccine could prevent some cases with unidentifiable type and multiple infections and the proportion of cases that it can offer benefit was estimated
by the prevalence of the five targeted HPV type relative to the prevalence of all non-16/18 types. In Scenario C, the 9-valent vaccine could offer full
protective benefits in cases with unidentifiable types and multiple infections.
doi:10.1371/journal.pone.0048426.g002
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of 3 teenage girls between 11 and 17 years old had received at least
one dose of currently available HPV vaccines [25]. However, by
assuming complete coverage, we were able to estimate the
maximum potential reductions of cervical cancer under the
different scenarios. In a real-world situation where uptake is
imperfect, the potential benefit of the 9-valent vaccine is expected
to decrease roughly proportionately to the percentage of uptake.
For example, in Kenya, if complete uptake offers 79.8% reduction
in lifetime risk of cervical cancer, then 50% uptake will offer
approximately half, or 40%, reduction. Note that this estimate
does not take into consideration potential herd immunity benefits
that may come into play when vaccine uptake is incomplete and
may make the reduction even greater.
To date, there is no evidence suggesting that the 9-valent HPV
vaccine will result in differentially higher uptake than currently
available vaccines. While protection against more HPV types
could be a strong incentive for individuals to obtain the vaccine,
there is not yet a clear advantage in how the vaccine will be
administered (e.g., parenteral versus oral routes) or in the number
of doses required. Vaccine uptake will continue to be a concern for
the 9-valent vaccine as well as for currently available vaccines.
In this study, we did not examine the impact of screening
programs on the absolute and added benefits from the 9-valent
vaccine; therefore, generalizability to settings that have screening
programs may be limited. In settings where effective screening
programs exist, we expect that the absolute and added health
benefits from the 9-valent vaccine would be reduced. Generally,
with more effective screening programs, the benefits of vaccination
are expected to be lower. This trend applies to both currently
available vaccines and the 9-valent vaccine. Countries without an
effective cervical cancer screening program are likely to achieve
greater added benefits from the 9-valent vaccine, compared to
countries where effective screening programs are in place.
We did not explore the benefits of vaccinating both boys and
girls with the 9-valent vaccine relative to vaccinating both sexes
Figure 3. Potential benefits of the 9-valent vaccine by HPV type distribution, multiple HPV infections and unidentifiable types in
Uganda. The whole pie chart represents all cervical cancer cases in Uganda. The slice of the blue pie on the right depicts those cases that caused by
non-16/18 types. The bar graph adjacent to the blue pie slice shows the proportion of the non-16/18 cases that are associated with multiple
infections and unidentifiable types. The remaining non-16/18 cases were estimated to be the 9-valent vaccine target and non-target by their HPV
prevalence. In the bar chart adjacent to the pie, blue shading depicts the cases that could be prevented by the 9-valent vaccine. In Scenario A, the 9-
valent vaccine could not offer any benefit to prevent cervical cancer with unidentifiable type and multiple infections. In Scenario B, the 9-valent
vaccine could prevent some cases with unidentifiable type and multiple infections and the proportion of cases that it can offer benefit was estimated
by the prevalence of the five targeted HPV type relative to the prevalence of all non-16/18 types. In Scenario C, the 9-valent vaccine could offer full
protective benefits in cases with unidentifiable types and multiple infections.
doi:10.1371/journal.pone.0048426.g003
Figure 4. Potential benefits of the 9-valent vaccine by HPV type distribution, multiple HPV infections, unidentifiable types, and
vaccine cross-protective effects in Kenya and Uganda. The bar graph depicts the potential benefits in reduction (%) of cervical cancer cases of
currently available vaccines and the 9-valent vaccine under the Scenarios A (no benefit to cases with unidentifiable HPV types and HPV co-infections),
B (partial benefit to cases with unidentifiable HPV types and HPV co-infections), and C (full benefit to cases with unidentifiable HPV types and HPV co-
infections) with varying levels of vaccine-cross protective benefits in Kenya and Uganda.
doi:10.1371/journal.pone.0048426.g004
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both sexes with the 9-valent vaccine would further reduce lifetime
risk of cervical cancer. Male HPV vaccination would also result in
direct health benefits to males (by preventing male HPV-related
diseases, such as genital warts, and anal, penile, and oral cancers),
as well as contribute to reduced HPV transmission in the
population, thus providing ‘‘indirect’’ benefits to sexual partners.
However, the burden of HPV-related diseases in males is relatively
low, and we have learned from previous analyses that the added
benefits from including boys in the vaccination program would
likely be less than the added benefits from increasing uptake in
girls [26]. Furthermore, there is limited information on the
prevalence and type distribution of the five additional HPV
genotypes in males and the transmission of the five additional
HPV types between sexual partners, which are critical inputs to
the evaluation. As more data become available on HPV in males,
an evaluation of the benefits of vaccination of both sexes with the
9-valent vaccine will be a priority. Ultimately, the decision to
expand the target population for HPV vaccination beyond young
girls will need to include considerations of program costs, the
burden of HPV-related diseases in males, the feasibility of
achieving effective coverage rates, and the desirability to
implement a gender-neutral vaccination program for ethical,
cultural, social, or practical reasons.
There are other noteworthy limitations. The estimated benefits
from HPV vaccination were restricted to squamous cell carcino-
mas of the cervix, as there is limited clinical and epidemiological
information on non-squamous cell types of cervical cancer. As a
result, the estimates may not be applicable to prevention of non-
squamous cell cancers. In addition, we did not make any
assumptions regarding the correlations between the four sources
of uncertainty in estimating vaccine benefits. For example, we did
not assume that cancer cases with unidentifiable types and
multiple infections occurred with a positive correlation. Informa-
tion from clinical trials may reveal negative or positive correlations
among these factors, and modeling the interactions between
different uncertainties may be feasible with such data.
Other factors should be considered in policy decisions regarding
adoption of the 9-valent vaccine. In this analysis, we assumed that
neither the current vaccines nor the 9-valent vaccine have serious
adverse side effects and compared only vaccine benefits in terms of
cancer reduction. Costs of the vaccines and implementation are
important factors that should be incorporated in future studies to
assess the value of the added benefits of the 9-valent vaccine.
Conclusions
The 9-valent HPV prophylactic vaccine is expected to offer
greater protection against cervical cancer than current vaccines.
The magnitude of this added benefit, however, is uncertain due to
the complex interactions of several factors; important among them
are HPV type distribution in cancer cases, cases that are
attributable to co-infections with multiple HPV types or uniden-
tifiable type(s), and vaccine cross-protection against non-vaccine
types. In this study, we leveraged a disease simulation model of
HPV-induced cervical cancer to estimate health gains in terms of
cervical cancer reductions associated with the 9-valent vaccine
under different scenarios. Type distribution of HPV in cancer
cases, and cancers attributable to multiple HPV infections and
unidentifiable HPV types can influence vaccine effectiveness
individually and jointly, but the magnitude of influence may be
moderated by vaccine cross-protective effects. These benefits must
be weighed against the cost of the vaccines in future analyses.
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